BridgeBio Oncology Therapeutics Inc. BBOT · Stock Open BridgeBio Oncology Therapeutics Inc. in new tab
Analyst price targets
Recent rating changes, newest first
BridgeBio Oncology Therapeutics Inc. Analysis (BBOT)
Is BridgeBio Oncology Therapeutics Inc. a good investment? BridgeBio Oncology Therapeutics Inc. (BBOT) is currently trading at 3.31 USD. Market analysts have a consensus price target of 24.55 USD. This suggests a potential upside from current levels.
Earnings Schedule: BridgeBio Oncology Therapeutics Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -2.72.
Investor FAQ
Does BridgeBio Oncology Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is BridgeBio Oncology Therapeutics Inc.?
BridgeBio Oncology Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.07.
Company Profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Community Discussion